Bond.az White LogoBond.az Black Logo

Goldman Sachs Starts Nationwide Health at Buy

Goldman Sachs starts Nationwide Health Properties with Buy rating and $20 target. Stock at $14.86, potential 35% gain.

Mia Lopez
ByMia Lopez- Senior Editor
|
0

Bond.az - Goldman Sachs initiated coverage on Nationwide Health Properties (NASDAQ:NHP) with a Buy rating and a price target of $20.00. The stock currently trades at $14.86, implying about 35% upside.

The firm cited progress in transitioning to a pure-play senior housing operating portfolio. Exposure to secondary and tertiary markets helps insulate from supply risks.

Goldman Sachs believes NHP's asset management team can drive portfolio improvements.

NHP has a market cap of $916 million and total debt of $1.04 billion. However, a current ratio of 3.5 indicates sufficient liquidity.

A $528 million OMF portfolio sale is under agreement. Additionally, $125 million in acquisitions are under agreement, with $275 million guided for 2026.

In other news, National Healthcare Properties reported strong Q1 2026 results. Normalized FFO was $7.5 million, or $0.26 per share, nearly double Q1 2025.

More News
Yesterday / 20:21
|
381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

0
Yesterday / 20:20
|
884

BofA raises Candel price target to $9

BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.

0
Yesterday / 18:11
|
808

Roblox rebounds on user growth, Needham says

Needham reiterates Roblox Buy rating amid user growth rebound. Stock has 27% upside to $60 target.

0
Yesterday / 17:51
|
287

US Tiger Securities Boosts Baidu Price Target on AI

US Tiger Securities raised Baidu price target to $160 on AI growth. AI revenue now exceeds half of business.

0
Yesterday / 15:50
|
224

AMAT and LRCX stocks defended by Lynx

Lynx Equity defends AMAT and LRCX stocks with bullish price targets of $540 and $325 respectively.

0
Yesterday / 14:45
|
827

DA Davidson Maintains Brunswick Stock Neutral

DA Davidson reaffirms Neutral rating on Brunswick with $76 target. Premium brands strong, value brands weak. Q1 2026 results beat estimates.

0
Yesterday / 14:43
|
834

D.A. Davidson Reaffirms Aebi Schmidt on Strong Orders

D.A. Davidson reaffirms Buy rating on Aebi Schmidt with $15 target. Strong order backlog up 23%. Revenue beats expectations. Get details on Bond.az.

0
Yesterday / 13:32
|
366

Freedom Broker Upgrades Kinross Gold Rating

Freedom Broker upgrades Kinross Gold to Buy with $38 target. Strong cash flow and record margins drive the upgrade.

0
Yesterday / 13:01
|
960

JPMorgan Reiterates Five Below Stock Rating with $306 Target

JPMorgan reiterates Overweight rating on Five Below with $306 price target, implying 43% upside potential.

0
Yesterday / 11:44
|
685

Elmet Stock Gets Overweight Rating

Cantor Fitzgerald starts Elmet Group with Overweight rating and $20 target. Defense and reshoring trends drive outlook.

0
Yesterday / 11:25
|
722

Truist Starts Arcus Biosciences at Buy on RCC Potential

Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.

0
Yesterday / 11:24
|
728

Revolution stock buy rating from Truist

Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.

0
...